Navigation Links
Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
Date:1/13/2009

Presentation Scheduled for Thursday, January 15th at 1:00PM PT

NEW YORK, Jan. 13 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, is scheduled to present at the J.P. Morgan 27th Annual Healthcare Conference being held in San Francisco.

Mr. Weiss' presentation will be webcast live on Thursday, January 15th at 1:00pm PT and will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. The Company also has an in-licensin
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
3. Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
4. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2008 Financial Results on Monday, May 12, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals to Present at the Deutsche Bank 33rd Annual Health Care Conference
7. Keryx Biopharmaceuticals Receives Nasdaq Notification
8. Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
9. Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
10. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
11. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Richardson, Texas (PRWEB) October 20, 2014 ... today announced that a team from Iowa State University ... * design contest. Using a Convey HC-2ex, the team’s ... than 14 times faster than the second place finisher. ... academic world embarked upon the month long challenge, using ...
(Date:10/20/2014)... PureTech , a science and ... problems, announced today the closing of a $55 ... Invesco Perpetual, a $120 Billion group of funds. ... existing pipeline forward and to advance new healthcare ... creativity to really go for the big ideas ...
(Date:10/19/2014)... 2014 OCTOBER 20-22, 2014: ... ABIM will take place at the ... ABIM 2014 is now available at ... companies and organizations from all over the ... on the latest products and developments on ...
(Date:10/19/2014)... report "Chocolate, Cocoa Beans, Lecithin, Sugar and Vanilla Market ... (2011 - 2016)," analyzes the chocolate market by ... market drivers, restraints, and opportunities for the chocolate market ... chocolate market is expected to grow from $83.2 billion ... CAGR of 2.7% from 2011 to 2016. , Get ...
Breaking Biology Technology:Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 2Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 4
... N.J., Sept. 17 Medarex, Inc.,(Nasdaq: MEDX ) ... the UBS,Global Life Sciences Conference at 4:30 p.m. Eastern ... webcast live and will be available in,the Investor Relations ... archived edition of the presentation will be available following ...
... Former Chair Of Psychology Department At Harvard University,Joins Panel Of ... ... Neurological Testing Company, BERKELEY, Calif., Sept. 17 NeuroFocus, ... for marketing,research, announced that professor Stephen Kosslyn, Ph.D. has joined ...
... LOUIS, Sept. 17 Sigma-Aldrich Corporation,(Nasdaq: SIAL ) ... Sciences,Conference on Wednesday, September 24th at 8:30 AM ET ... may listen via live audio broadcast over the,Internet available ... to access this file. For the webcast on, http://ir.sigmaaldrich.com ...
Cached Biology Technology:Neurofocus Appoints Stephen Kosslyn to Its Advisory Board 2
(Date:10/17/2014)... . To date, ... overdoses, doctors are often limited to supportive therapy such as ... combination of drugs involved. So what can be done if ... ETH professor Jean-Christophe Leroux from the Institute of Pharmaceutical Sciences ... question. "The task was to develop an agent that could ...
(Date:10/16/2014)... synthesis of recent research findings to inform their management ... states. , The Ecology and Management of Moist ... of the Relevant Biophysical Science and Implications for Future ... U.S. Forest Service,s Pacific Northwest Research Station, is a ... synthesis of the large body of scientific information on ...
(Date:10/16/2014)... tract infections and worldwide claims the lives of ... Ghent University have succeeded in developing a promising ... , Xavier Saelens (VIB/UGent): "We discovered a ... the development of a novel approach to vaccination ... numerous small children and elderly people." , ...
Breaking Biology News(10 mins):Emergency aid for overdoses 2Emergency aid for overdoses 3New report synthesizes best available science on management of moist mixed-conifer forests 2New perspectives for development of an RSV vaccine 2
... A great deal of science learning takes place ... for example, and through TV programs, books, and online ... new from the National Research Council, recommends ways museum ... foster science learning for people of all ages, backgrounds, ...
... An Australian method for assessing the environmental impact of ... agencies worldwide. Aspects of the ,ecological risk assessment, ... Ecuador, and the Western and Central Pacific, and by ... The method was developed in research led by Dr ...
... Two junior researchers from Ludwig-Maximilians-Universitt (LMU) in ... the European Research Council (ERC). Professor Jens Michaelis, ... David Vhringer, Institute of Immunology, shall receive grants ... five years. With its Starting Grant, the ERC ...
Cached Biology News:World interest in Australian fishery impact test 2LMU Munich researchers highly endowed with EU funding 2
Designed for use with any of the Agencourt kits in tube format....
... (4,6-diamidine-2-phenylindole, dihydrochloride) is a fluorescent ... blue in color. The bright ... to red fluorochromes such as ... R-Phycoerythrin. DAPI can be used ...
... cytochrome P450 (CYP450) metabolite postulated to play ... cerebral vasculature. In rat cerebral microvessels, 20-HETE ... vasoconstriction. 20-HETE is excreted mainly as the ... (20-40 pg/ml in human urine) is about ...
... APAgene kits are designed to rapidly ... using our patented APA Technology. APAgene provides ... competitive price. All necessary ingredients are provided ... can be used for gap filling, localized ...
Biology Products: